Marketing-authorisation holder · United States
Eli Lilly and Company
57 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
57 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 57
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADCIRCA20mg · Tablet | Tadalafil | United States | Marketed | 2009 |
| AXIRON30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution, metered | Testosterone | United States | Not marketed | 2010 |
| Basaglar300units/3ml (100units/ml) · Injection | Insulin glargine | United States | Marketed | 2019 |
| BASAGLAR300 units/3ml (100 units/ml) · Solution | Insulin glargine | United States | Marketed | 2015 |
| CYRAMZA100mg/10ml | 500mg/50ml · Injectable | Ramucirumab | United States | Marketed | 2014 |
| Ebglyss250mg/2ml · Injection | Lebrikizumab | United States | Marketed | 2024 |
| EBGLYSS250mg/2ml · Injectable | Lebrikizumab | United States | Marketed | 2024 |
| Emgality100mg/ml · Injection | Galcanezumab | United States | Marketed | 2019 |
| Emgality120mg/ml · Injection | Galcanezumab | United States | Marketed | 2018 |
| EMGALITY120mg/ml · Injectable | Galcanezumab | United States | Marketed | 2018 |
| FOUNDAYO0.8mg base | 14.5mg base | 17.2mg base | 2.5mg base | 5.5mg base | 9mg base · Tablet | Orforglipron | United States | Marketed | 2026 |
| Humalog300units/3ml (100units/ml) · Injection | Insulin lispro | United States | Marketed | 1996 |
| Humalog600units/3ml (200units/ml) · Injection | Insulin lispro | United States | Marketed | 2025 |
| HUMALOG KWIKPEN200 units/ml · Solution | Insulin lispro recombinant | United States | Marketed | 2015 |
| Humulin 70/30210units/3ml (70units/ml); 90units/3ml (30units/ml) · Injectable Suspension | Insulin (human) | United States | Marketed | 2013 |
| Humulin N300units/3ml (100units/ml) · Injectable Suspension | Insulin (human) | United States | Marketed | 2013 |
| Humulin N300units/3ml (100units/ml) · Injectable Suspension | Insulin (human) | United States | Marketed | 1982 |
| Humulin R U-100300units/3ml (100units/ml) · Injection | Insulin (human) | United States | Not marketed | 1998 |
| INLURIYO200mg base · Tablet | Imlunestrant | United States | Marketed | 2025 |
| KISUNLA350mg/20ml(17.5mg/ml) · Injectable | Donanemab | United States | Marketed | 2024 |
| LARTRUVO500mg/50ml · Injectable | Olaratumab | United States | Marketed | 2016 |
| Lyumjev300units/3ml (100units/ml) · Injection | Insulin lispro | United States | Marketed | 2020 |
| Lyumjev300units/3ml (100units/ml) · Injection | Insulin lispro | United States | Not marketed | 2020 |
| LYUMJEV100units/ml(u-100) | 200units/ml(u-200) · Injectable | Insulin lispro | United States | Marketed | 2020 |
| Lyumjev600units/3ml (200units/ml) · Injection | Insulin lispro | United States | Marketed | 2020 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 57 | 54 | 3 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
GLEIF; exact source URLs/locators, version status and retrieval dates. Normalized by Prognia; no official endorsement.
Licence: CC0
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.